Singapore Firm Abandons Plans for Stem Cell Therapies
By Dennis Normile,
Science
| 07. 20. 2007
In a sign that hopes for quick medical benefits from stem cells are fading, ES Cell International (ESI)--a company established with fanfare in Singapore 7 years ago--is halting work on human embryonic stem (hES) cell therapies. Investors lost interest because "the likelihood of having products in the clinic in the short term was vanishingly small," says Alan Colman, a stem cell pioneer who until last month was ESI's chief executive.
ESI's setback may dampen investors' enthusiasm for stem cell therapies, says Robert Lanza, vice president for R&D at Advanced Cell Technology in Worcester, Massachusetts: "What the field badly needs is one or two success stories."
Colman, a member of the team that cloned the sheep Dolly, will become head of the Singapore Stem Cell Consortium, which funds research at institutes affiliated with Singapore's Agency for Science, Technology and Research (A*STAR) and also offers grants. He will also set up a lab at A*STAR's Institute of Molecular and Cell Biology. Most of the 24 scientists working on hES cell therapies at ESI will continue their research with "more secure government funding"...
Related Articles
A Review of Exposed by Becky McClain
“Do not get lost in a sea of despair. Be hopeful, be optimistic. Our struggle is not the struggle of a day, a week, a month, or a year, it is the struggle of a lifetime. Never, ever be afraid to make some noise and get in good trouble, necessary trouble.”
— John Lewis
Becky McClain became famous when she successfully sued Pfizer, one of the very largest pharmaceutical and biotech companies. She...
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
